Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 59 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NPH human insulin Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more

Conditions: Diabetes, Gestational, Diabetes, Type 2
Interventions: Insulin; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperglycemia
Interventions: NPH insulin plus Complete Insulin Orders, Complete Insulin Orders; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: GLP-1 receptor agonist, Insulin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin human, insulin lispro, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions: NPH Insulin, glargine, Insulin Aspart; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, insulin NPH; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more

Conditions: Diabetes Mellitus, Type 2
Interventions: DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 550,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more

Conditions: Type 2 Diabetes Mellitus
Interventions: NPH and regular insulin, glargine and humalog; Drug
Lead sponsor: Riverside University Health System Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Moreno Valley, California

Conditions: Diabetes Mellitus
Interventions: Generex Oral-lyn™, Regular human insulin; Drug
Lead sponsor: Generex Biotechnology Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: 2001 Santa Monica Blvd Suite 390W, California • 1150 N. 35th Ave Suite 590, Florida • 7400 North Shadeland Ave, Indiana + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Tempe, Arizona • Concord, California • Fresno, California + 17 more

Conditions: Diabetes Mellitus, Type 2
Interventions: insulin glargine, NPH human insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes
Interventions: Lantus and short acting analogs Vs NPH and short acting analogs; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Gestational Diabetes
Interventions: human insulin, insulin NPH, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Diabetes Mellitus
Interventions: Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions: Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 40 Years to 79 Years
Enrollment: 10,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 6
States / cities: Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Diabetes
Interventions: Switching to NPH insulin, Continuation of insulin glargine; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: Up to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Insulin glulisine, insulin lispro, insulin glargine, NPH insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Insulin detemir, Glargine, NPH; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 1,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 2 Diabetes Mellitus
Interventions: GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fresno, California

Conditions: Prevention of New Onset Diabetes Among Kidney Transplant Patients
Interventions: Insulin treatment for hyperglycemia; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes, Type 2
Interventions: Glargine, NPH; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Type 2 Diabetes
Interventions: Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 70 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: La Jolla, California • Norwalk, California • Miami, Florida + 10 more

Search by objective public record fields.

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Lantus in the Treatment of Type 1 Diabetes Children

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Comparison Study of Insulin Glargine and NPH Insulin

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

A Clinical Trial to Prevent New Onset Diabetes After Transplantation

The Inova Type 2 Diabetes Mellitus Study

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients